{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-26-008204","form_type":"8-K","ticker":"INMB","cik":"0001711754","company_name":"Inmune Bio, Inc.","filed_at":"2026-01-27T23:59:59+00:00","discovered_at":"2026-05-14T18:02:35.971578+00:00","generated_at":"2026-05-16T07:33:43.076826+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"INmune Bio updates on CORDStrom RDEB timing and XPro Alzheimer's Phase 2 results","bullets":["CORDStrom commercial pilot runs completed; MAA to UK MHRA planned mid-2026; BLA to FDA targeted end of 2026.","XPro Phase 2 MINDFuL missed primary endpoint in broad population (n=200) but showed cognitive effect (EMACC d=0.27) in biomarker-defined subpopulation (n=100).","Cash position $27.7M as of Sept 30, 2025, expected to fund operations through year-end 2026.","XPro reduced pTau217 and neuroimaging suggested reduced neurodegeneration in the subgroup.","Regulatory timelines for CORDStrom and XPro remain subject to feedback and manufacturing readiness."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-26-008204","json":"https://secwatch.observer/filing/0001213900-26-008204.json","markdown":"https://secwatch.observer/filing/0001213900-26-008204.md","text":"https://secwatch.observer/filing/0001213900-26-008204.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1711754/000121390026008204/0001213900-26-008204-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1711754/000121390026008204/ea0274317-8k_inmune.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T07:33:43.076826+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}